Navigation Links
Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children
Date:2/26/2009

RALEIGH, N.C., Feb. 26 /PRNewswire/ -- Arbor Pharmaceuticals, a specialty pharmaceutical company focused exclusively on pediatric medicine, announced today that the company has launched XYLAREX - a first-in-class nonantibiotic for the dietary management of recurrent acute otitis media (middle ear infections). XYLAREX is a novel oral solution intended to be administered daily to reduce the number of ear infections children experience. The primary ingredient in XYLAREX has also been shown to reduce the amount of antibiotics prescribed to children affected by middle ear infections. XYLAREX can be administered to children as young as six months of age.

Acute Otitis Media (AOM) is the most common bacterial illness of childhood and the primary reason antibiotics are prescribed for children in the U.S. Recurrent AOM affects millions of U.S. children each year, and children suffering from repeated, painful ear infections are frequently exposed to numerous courses of antibiotics at a young age. With repeated antibiotic exposure there is an increased risk of developing bacterial resistance, which the Centers for Disease Control and Prevention (CDC) call one of the world's most pressing health concerns.

"Until now there have been limited options for managing children with recurrent acute otitis media. Pediatricians and otolaryngologists alike see many children with recurrent ear infections who have been subjected to countless antibiotic courses and - in severe cases - may require ear tube placement to alleviate symptoms. Parents and clinicians are looking for new options for these children. A novel, non-drug product like XYLAREX is an important new option for managing children with recurrent AOM in order to reduce their infections and decrease their need for antibiotics," says Mark Mehle, M.D., a practicing ear, nose, and throat physician in Cleveland, Ohio.

According to Jarrett Disbrow, Presiden
'/>"/>

SOURCE Arbor Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. A classic method for modeling skin cancer is featured in Cold Spring Harbor Protocols
2. Cold Spring Harbor scientists devise novel, low-cost method of sifting genomes high-value regions
3. Cold Spring Harbor Protocols features innovative methods for embryology research
4. Cold Spring Harbor Laboratory researchers race against time to save Tasmanian devils
5. Cold Spring Harbor Protocols features high-throughput methods for analyzing gene activity
6. Harborview Medical Center Implements Latest Release of the DocuSys Solution to Improve Anesthesia Medication Safety and Documentation
7. SEIU RN Dian Palmer Calls on AFL-CIO Head John Sweeney to Review Video From Dearborn Protest, Retract Statement Accepting CNA Distortions
8. Does 1q31.1-32.1 harbor a tumor suppressor gene related to Chinese SCC patients?
9. Cold Spring Harbor scientists reveal a proteins role in enabling AIDS virus to reproduce
10. Cold Spring Harbor science teams identify 13 new tumor-suppressor genes in liver cancer
11. Announcing a Monumental Sharing of Laser Innovation: The American Society for Laser Medicine and Surgery (ASLMS) Holds 29th Annual Conference in National Harbor, Md., April 1 - 5, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... Researchers have found that fecal transplantation is effective ... immunocompromised patients. This is the result of a study ... Center for Women,s Gastrointestinal Medicine at The Women,s Medicine ... online in advance of print in the American ... or C. diff , has increased to epidemic ...
(Date:7/9/2014)... news release is available in French . ... factors in 14 year old teens, including brain structure and ... 70% accuracy who will go on to develop binge drinking ... of conscientiousness, and other variables such as life events and ... of binge drinking. Whether or not the child had ...
(Date:7/9/2014)... is for more than watching World Cup highlights, Brian ... skateboarders landing in unfortunate positions on railings. A University ... Dermatology Online Journal shows that YouTube also allows ... the public on topics of skin cancer and prevention. ... is the future of how we communicate around the ...
(Date:7/9/2014)... 9, 2014) A retrospective study conducted by researchers ... reports that among adults with intellectual and developmental disabilities, ... of years receiving dental care increased. The findings, published ... Dentistry , may help improve interventions designed to address ... , The researchers reviewed the dental records of 107 ...
(Date:7/9/2014)... 9, 2014 A study published in the scientific ... and Robert Bonin, two researchers at Universit Laval, reveals ... a new method that involves rekindling pain so that ... to novel means to alleviate chronic pain. , The ... and Institut universitaire en sant mentale de Qubec (IUSMQ) ...
Breaking Medicine News(10 mins):Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:What drives a child to abuse alcohol? 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Discovery of a new means to erase pain 2
... productivity industry, WASHINGTON, March 31 The ... on Health (NBCH), two,nationally-recognized non-profit organizations focused on ... and quality of life, are,partnering to host the ... will take place February 9-11, 2009 at the ...
... of elderly patients could cut their total mortality by ... a third, according to a new study presented today ... in Chicago and published simultaneously in the New England ... the Very Elderly Trial (HYVET), which is coordinated by ...
... Chicago, IL, March 31, 2008 New data ... technology found that in patients living with type ... burden in the coronary arteries compared to glimepiride, ... data stem from the PERISCOPE (Pioglitazone Effect on ...
... DIEGO, March 31 Amira Pharmaceuticals, a small,molecule ... of,compounds to treat inflammatory disease, today announced the ... directors: Dennis M. Fenton, Ph.D.,and Stephen W. Kaldor, ... pharmaceutical and biotechnology experience,including over two decades at ...
... Focus on Delivering on ... 2008 Free Cash Flow Target, SIOUX ... the leading provider of media and,connectivity solutions to hospitality and healthcare ... Conference at The Palms,Hotel in Las Vegas on Wednesday, April 2. ...
... 31 Greenway Medical Technologies,announced today its expanded ... Quality Reporting Initiative (PQRI) and Pay for,Performance (P4P) ... technology (HIT) adoption., The PQRI, which was ... Medicare, Medicaid, and SCHIP Extension Act of 2007, ...
Cached Medicine News:Health News:Integrated Benefits Institute and National Business Coalition on Health to Host First Annual Health and Productivity Forum 2Health News:Significant reductions in mortality shown using blood pressure-lowering treatment in very elderly 2Health News:Significant reductions in mortality shown using blood pressure-lowering treatment in very elderly 3Health News:New data showed Actos prevented progression of atherosclerotic plaque volume in patients 2Health News:Dr. Dennis Fenton and Dr. Steve Kaldor Join Amira Board of Directors 2Health News:LodgeNet Interactive to Present at The B. Riley Investor Conference 2Health News:LodgeNet Interactive to Present at The B. Riley Investor Conference 3Health News:LodgeNet Interactive to Present at The B. Riley Investor Conference 4Health News:LodgeNet Interactive to Present at The B. Riley Investor Conference 5Health News:Greenway Medical Technologies Expands Support for Physician Quality Reporting Initiative and Pay for Performance Programs 2Health News:Greenway Medical Technologies Expands Support for Physician Quality Reporting Initiative and Pay for Performance Programs 3Health News:Greenway Medical Technologies Expands Support for Physician Quality Reporting Initiative and Pay for Performance Programs 4
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... on study results demonstrating survival advantage ... months when added to standard therapy, -- First study ... BOULDER, Colo., Jan. 24 Pharmion Corporation,(Nasdaq: PHRM ) ... positive opinion to recommend approval of Thalidomide,Pharmion(R) for use in ...
... with Fractionated Lasers Or in ... the Eyes, WALTHAM, Mass., Jan. 24 When it ... no longer the only option. According to the,American Academy of ... who is interested in non-surgical options to obtain the,best results. ...
Cached Medicine Technology:Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 2Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 3Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 4Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 5Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 6Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes 2Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes 3Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes 4
Portex® Blue Line® cuffed endotracheal tubes come in a wide selection of sizes, each with a standard 15 mm ISO connector., ,Portex® Blue Line® endotracheal tubes are recognized world...
... PVC. 2 eyes, oral. Marked with ... X-ray opaque line. Graduated. Single use. ... reduce kinking of the tube by ... adapts to the anatomical situation at ...
... Ruschelit® PVC. Murphy eye-oral. High volume/low ... Oral Cuffed Single use. For improved ... of the tube by incorporating a ... cuff. Thermosensitive Ruschelit® PVC adapts to ...
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. Murphy eye. High volume/low pressure cuff. Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Steri...
Medicine Products: